Stemtech CORP 10-Q quarterly reports

Stemtech Corporation's Q2 2026 Form 10-Q reveals a significant decline in net sales and continued net losses, highlighting ongoing financial pressures and operational constraints.

Stemtech Corporation reported a significant net sales decline and recurring losses, raising substantial doubt about its ability to continue as a going concern, despite cost-cutting and strategic expansion efforts.

Stemtech Corporation reported a reduced net loss in Q2 2025 despite a significant drop in net sales, driven by aggressive cost management and a strategic recalibration.

Stemtech Corporation reported a higher net loss for Q1 2025 compared to the prior year, driven by decreased net sales despite significant reductions in operating and interest expenses, while facing substantial doubt about its ability to continue as a going concern.

Stemtech Corporation's Q3 2024 results show a slight increase in net sales but a significant net loss, highlighting ongoing challenges and restructuring efforts.

Stemtech Corporation's Q2 2024 results show a revenue increase compared to the same period last year, but the company continues to face significant financial challenges and operating losses.

Stemtech Corporation's Q1 2024 results show a rise in net sales and a decrease in operating loss compared to the same period last year, alongside ongoing efforts to manage debt and expand its business.